Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment
Open accessThe DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Abstract
The role of sirtuin 6 (SIRT6) in atherosclerotic progression of diabetic patients is unknown. We evaluated SIRT6 expression and the effect of incretin-based therapies in carotid plaques of asymptomatic diabetic and nondiabetic patients. Plaques were obtained from 52 type 2 diabetic and 30 nondiabetic patients undergoing carotid endarterectomy. Twenty-two diabetic patients were treated with drugs that work on the incretin system, GLP-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors for 26 ± 8 months before undergoing the endarterectomy. Compared with nondiabetic plaques, diabetic plaques had more inflammation and oxidative stress, along with a lesser SIRT6 expression and collagen content. Compared with non-GLP-1 therapy–treated plaques, GLP-1 therapy–treated plaques presented greater SIRT6 expression and collagen content, and less inflammation and oxidative stress, indicating a more stable plaque phenotype. These results were supported by in vitro observations on endothelial progenitor cells (EPCs) and endothelial cells (ECs). Indeed, both EPCs and ECs treated with high glucose (25 mmol/L) in the presence of GLP-1 (100 nmol/L liraglutide) presented a greater SIRT6 and lower nuclear factor-κB expression compared with cells treated only with high glucose. These findings establish the involvement of SIRT6 in the inflammatory pathways of diabetic atherosclerotic lesions and suggest its possible positive modulation by incretin, the effect of which is associated with morphological and compositional characteristics of a potential stable plaque phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In diabetic patients treated with GLP-1-based therapy, the protein level of SIRT6 in asymptomatic plaques was significantly increased and TNF-α and MMP-9 levels in lesions were significantly reduced compared with diabetic patients without treatment [8].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [8]
In the citing paper
“Liraglutide (100 nM) treatment increased SIRT6 expression and reduced NF-κB expression compared with only high glucose-treated endothelial cells.”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [8]
In the citing paper
“More importantly, compared with non-GLP-1RA/DPP-4i-treated plaques, GLP-1RA/DPP-4i-treated plaques presented greater SIRT6 expression and collagen content, with less inflammation and oxidative stress, indicating a more stable plaque phenotype and suggesting that GLP-1RAs can reduce plaque vulnerability [58].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [58]
In the citing paper
“Compared with non-diabetic plaques, diabetic plaques had more inflammation and oxidative stress, along with a lower sirtuin (SIRT)6 expression and less interstitial collagen content.”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [58]
In the citing paper
“More importantly, compared with non-GLP-1RA/DPP-4i-treated plaques, GLP-1RA/DPP-4i-treated plaques presented greater SIRT6 expression and collagen content, with less inflammation and oxidative stress, indicating a more stable plaque phenotype and suggesting that GLP-1RAs can reduce plaque vulnerability [58].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [58]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I
Creager, M. A., Lüscher, T. F., of, P. W. T. A., Cosentino, F., & Beckman, J. A. (2003) · Circulation · doi:10.1161/01.cir.0000091257.27563.32 · Cited by 1,650
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444
Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., & Horikawa, I. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-01-0033 · Cited by 1,364
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin
Michishita, E., McCord, R. A., Berber, E., Kioi, M., Padilla-Nash, H., Damian, M., Cheung, P., Kusumoto, R., Kawahara, T. L. A., Barrett, J. C., et al. (2008) · Nature · doi:10.1038/nature06736 · Cited by 1,111 · cited 1×
“GLP-1 levels (Active GLP-1 [7-36] Specific ELISA Kit; Epitope Diagnostics) were measured after an overnight fast (at 8:00 A.”
MethodKawahara, T. L. A., Michishita, E., Adler, A. S., Damian, M., Berber, E., Lin, M., McCord, R. A., Ongaigui, K. C. L., Boxer, L. D., Chang, H. Y., et al. (2009) · Cell · doi:10.1016/j.cell.2008.10.052 · Cited by 1,090
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“GLP-1 levels (Active GLP-1 [7-36] Specific ELISA Kit; Epitope Diagnostics) were measured after an overnight fast (at 8:00 A.”
Method
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“Studies in humans have partially confirmed antiinflammatory [162] and anti-atherosclerotic actions of GLP-1 RAs [163].”
BackgroundIncalza, M. A., D'Oria, R., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.05.005 · Cited by 1,356
“SIRT6, another NAD-dependent deacetylase, is expressed at low levels in atherosclerotic lesions from human patients [280-281].”
BackgroundThe Role of Sirtuins in Antioxidant and Redox Signaling
Singh, C. K., Chhabra, G., Ndiaye, M. A., Garcia-Peterson, L. M., Mack, N. J., & Ahmad, N. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7290 · Cited by 812
“The delineation of SIRT6-mediated deacetylation on histone 3 uncovered the roles it possessed in chromatin regulation and gene expression through recruitment of certain transcription factors such as NF-jB (69, 70, 188).”
BackgroundInfluentialNauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
“In diabetic patients treated with GLP-1-based therapy, the protein level of SIRT6 in asymptomatic plaques was significantly increased and TNF-α and MMP-9 levels in lesions were significantly reduced compared with diabetic patients without treatment [8].”
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside
Winnik, S., Auwerx, J., Sinclair, D. A., & Matter, C. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv290 · Cited by 422
“In parallel, Sirt6 expression and inflammatory activity in diabetic atherosclerotic plaques increased upon incretin treatment and was associated with a more stable plaque phenotype.(71)”
BackgroundSIRT1 and SIRT6 Signaling Pathways in Cardiovascular Disease Protection
D'Onofrio, N., Servillo, L., & Balestrieri, M. L. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7178 · Cited by 388
“Indeed, carotid atherosclerotic plaques from type 2 diabetic patients displayed reduced SIRT6 expression compared with plaques from nondiabetic patients (16).”
BackgroundInfluentialSelf-citationSirtuins and Type 2 Diabetes: Role in Inflammation, Oxidative Stress, and Mitochondrial Function
Kitada, M., Ogura, Y., Monno, I., & Koya, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00187 · Cited by 288
Sirtuins, Cell Senescence, and Vascular Aging
Kida, Y., & Goligorsky, M. S. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.11.022 · Cited by 256
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
Sosnowska, B., Mazidi, M., Penson, P., Gluba-Brzózka, A., Rysz, J., & Banach, M. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.027 · Cited by 187
Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics
Xu, S., Kamato, D., Little, P. J., Nakagawa, S., Pelisek, J., & Jin, Z. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.003 · Cited by 173
SIRT6 in Aging, Metabolism, Inflammation and Cardiovascular Diseases
Guo, Z., Li, P., Ge, J., & Li, H. (2022) · Aging and Disease · doi:10.14336/ad.2022.0413 · Cited by 173
“A GLP-1 receptor agonist (GLP-1RA) and an SGLT2 inhibitor (SGLT2i) were shown to stabilize plaques in diabetic patients by upregulating SIRT6 [217, 218].”
BackgroundAntidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Scheen, A. J., Esser, N., & Paquot, N. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.02.003 · Cited by 171
Mita, T., Katakami, N., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., Shiraiwa, T., Kosugi, K., Umayahara, Y., Yamamoto, T., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0781 · Cited by 159
“(30) used immunohistochemistry to determine the expres-”
ResultLi, W., Feng, W., Su, X., Luo, D., Li, Z., Zhou, Y., Zhu, Y., Zhang, M., Chen, J., Liu, B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150051 · Cited by 157
Mita, T., Katakami, N., Shiraiwa, T., Yoshii, H., Onuma, T., Kuribayashi, N., Osonoi, T., Kaneto, H., Kosugi, K., Umayahara, Y., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2145 · Cited by 148
“Interestingly, a recent report suggested that evaluation of local inflammation and oxidative stress in the vascularwall, not in serum,was helpful in the full assessment of “non-glycaemicdependent” antiatherosclerotic effects of DPP-4 inhibitors (30).”
BackgroundD’Onofrio, N., Servillo, L., Giovane, A., Casale, R., Vitiello, M., Marfella, R., Paolisso, G., & Balestrieri, M. L. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.013 · Cited by 145
Self-citationHyperglycemic Stress and Carbon Stress in Diabetic Glucotoxicity
Luo, X., Wu, J., Jing, S., & Yan, L. (2016) · Aging and Disease · doi:10.14336/ad.2015.0702 · Cited by 164
“However, sirtuins are NAD-dependent deacetylases and are unfortunately usually down-regulated in diabetes [251, 263-267].”
BackgroundFactors and Pathways Modulating Endothelial Cell Senescence in Vascular Aging
Hwang, H. J., Kim, N., Herman, A. B., Gorospe, M., & Lee, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710135 · Cited by 149
“SIRT6 prevents the formation of volatile atherosclerotic plaques in diabetic patients, and silencing SIRT6 suppresses EC replication and promotes EC senescence [77,78].”
BackgroundSIRT6 protects against endothelial dysfunction and atherosclerosis in mice
Xu, S., Yin, M., Koroleva, M., Mastrangelo, M. A., Zhang, W., Bai, P., Little, P. J., & Jin, Z. G. (2016) · Aging · doi:10.18632/aging.100975 · Cited by 118
Sirtuin 6: linking longevity with genome and epigenome stability
Korotkov, A., Seluanov, A., & Gorbunova, V. A. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.06.009 · Cited by 132
D’Onofrio, N., Sardu, C., Trotta, M. C., Scisciola, L., Turriziani, F., Ferraraccio, F., Panarese, I., Petrella, L., Fanelli, M., Modugno, P., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101337 · Cited by 116
Self-citationGLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Park, B., Bakbak, E., Teoh, H., Krishnaraj, A., Dennis, F., Quan, A., Rotstein, O. D., Butler, J., Hess, D. A., & Verma, S. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00574.2023 · Cited by 130
Sirtuins in vascular diseases: Emerging roles and therapeutic potential
D’Onofrio, N., Vitiello, M., Casale, R., Servillo, L., Giovane, A., & Balestrieri, M. L. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.03.001 · Cited by 111
“In vitro experiments on EPC and EC showed that the loss of SIRT6 during short-term exposure to high-glucose is paralleled by the increased expression of NF- B whereas overexpression of SIRT6 in the presence of cotreatmentwithGLP-1 receptor agonists relates to a decreased NF- B expression [107].”
BackgroundInfluentialSelf-citationVitiello, M., Zullo, A., Servillo, L., Mancini, F. P., Borriello, A., Giovane, A., Ragione, F. D., D’Onofrio, N., & Balestrieri, M. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.008 · Cited by 109
Self-citationSardu, C., D’Onofrio, N., Torella, M., Portoghese, M., Loreni, F., Mureddu, S., Signoriello, G., Scisciola, L., Barbieri, M., Rizzo, M. R., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0931-0 · Cited by 100
Self-citationMarfella, R., Sardu, C., Balestrieri, M. L., Siniscalchi, M., Minicucci, F., Signoriello, G., Calabrò, P., Mauro, C., Pieretti, G., Coppola, A., et al. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0304-3 · Cited by 97
“GLP-1 levels (Active GLP-1 [7-36] Specific ELISA Kit; Epitope Diagnostics) were measured after an overnight fast (at 8:00 A.”
MethodResultSelf-citationLiberale, L., Gaul, D. S., Akhmedov, A. T., Bonetti, N. R., Nageswaran, V., Costantino, S., Pahla, J., Weber, J., Fehr, V., Vdovenko, D., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz712 · Cited by 96
Shi, L., Ji, Y., Jiang, X., Zhou, L., Xu, Y., Li, Y., Jiang, W., Meng, P., & Liu, X. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0177-4 · Cited by 91
Sirtuin 6 overexpression relieves sepsis-induced acute kidney injury by promoting autophagy
Zhang, Y., Wang, L., Meng, L., Cao, G., & Wu, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1568746 · Cited by 91
Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets
Grootaert, M. O. J., & Bennett, M. R. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00685-x · Cited by 92
Casper, E. A. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122007 · Cited by 95
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 89
Ergothioneine Antioxidant Function: From Chemistry to Cardiovascular Therapeutic Potential
Servillo, L., D'Onofrio, N., & Balestrieri, M. L. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000464 · Cited by 81
Self-citationMarfella, R., Prattichizzo, F., Sardu, C., Rambaldi, P. F., Fumagalli, C., Marfella, L. V., Grotta, R. L., Frigé, C., Pellegrini, V., D’Andrea, D., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02118-6 · Cited by 101
Self-citationMarfella, R., Sardu, C., Calabrò, P., Siniscalchi, M., Minicucci, F., Signoriello, G., Balestrieri, M. L., Mauro, C., Rizzo, M. R., Paolisso, G., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13122 · Cited by 80
“GLP-1 levels (active GLP-1 [7-36] specific ELISA kit; Epitope Diagnostics, San Diego, California) were measured after an overnight fast (at 8:00 AM) and after breakfast in patients with diabetes.”
Self-citationXia, L., Sun, C., Zhu, H., Zhai, M., Zhang, L., Jiang, L., Hou, P., Li, J., Li, K., Liu, Z., et al. (2020) · Journal of Pineal Research · doi:10.1111/jpi.12661 · Cited by 75
Liu, Z., Wang, J., Huang, X., Li, Z., & Liu, P. (2016) · Translational research · doi:10.1016/j.trsl.2016.02.005 · Cited by 72
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
SIRT6 in Senescence and Aging-Related Cardiovascular Diseases
Li, X., Liu, L., Li, T. X., Liu, M., Wang, Y., Ma, H., Mu, N., & Wang, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641315 · Cited by 85
Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?
Prattichizzo, F., Giuliani, A., Nigris, V. D., Pujadas, G., Çeka, A., Sala, L. L., Genovese, S., Testa, R., Procopio, A. D., Olivieri, F., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12688 · Cited by 72
Bifari, F., Manfrini, R., Dei, M., Berra, C., Siano, M., Zuin, M. G., Paroni, R. C., & Folli, F. B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 75
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
Lg, S., Дігтяр, Н. І., Селіхова, Л. Г., Кайдашева, Е. І., Shlykova, O. A., Vesnina, L. E., & Кайдашев, І. П. (2019) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2019-0003 · Cited by 81
Yang, Y., Tian, T., Wang, Y., Li, Z., Xing, K., & Tian, G. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172516 · Cited by 70
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“Finally, there is also evidence to support that GLP-1R agonism can stabilise plaques not only by limiting inflammation and oxidative stress but also by increasing the expression of sirtuin 6, a DNA repair deacetylase [145].”
BackgroundSirt6 deficiency results in progression of glomerular injury in the kidney
Huang, W., Liu, H., Zhu, S., Woodson, M., Liu, R., Tilton, R. G., Miller, J. D., & Zhang, W. (2017) · Aging · doi:10.18632/aging.101214 · Cited by 71
Roles of Sirtuins in Cardiovascular Diseases: Mechanisms and Therapeutics
Ding, Y.-N., Wang, H.-Y., Chen, X.-F., Tang, X., & Chen, H. (2025) · Circulation Research · doi:10.1161/circresaha.124.325440 · Cited by 73
Targeting the epigenome in in-stent restenosis: from mechanisms to therapy
Yang, X., Yang, Y., Guo, J., Meng, Y., Li, M., Yang, P., Liu, X., Aung, L. H. H., Yu, T., & Li, Y. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.01.024 · Cited by 61
“The protective effect of SIRT6 on endothelial function is attributed to promoting endothelial-dependent vasodilation and bioavailability of vascular NO, reducing cell permeability, improving endothelial senescence and apoptosis, and promoting autophagy.132 Accumulating research has demonstrated that SIRT6 deficiency e…”
BackgroundThe Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
Dewanjee, S., Vallamkondu, J., Kalra, R. S., Chakraborty, P., Gangopadhyay, M., Sahu, R., Medala, V. K., John, A. A., Reddy, P. H., Feo, V. D., et al. (2021) · Cells · doi:10.3390/cells10061340 · Cited by 71
“Incretin treatment attenuates diabetic atherosclerosis in T2DM patients; however, SIRT6-attenuated inflammation in atherosclerotic lesions was regarded to potentiate the therapeutic effect of incretin [327].”
BackgroundSirtuins and Renal Oxidative Stress
Ogura, Y., Kitada, M., & Koya, D. (2021) · Antioxidants · doi:10.3390/antiox10081198 · Cited by 69
Ciarlo, E., Heinonen, T., Théroude, C., Herderschee, J., Mombelli, M., Lugrin, J., Pfefferlé, M., Tyrrell, B. E., Lensch, S., Acha‐Orbea, H., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01037 · Cited by 64
Khalyfa, A., Marín, J. M., Qiao, Z., Sánz-Rubio, D., Gozal, D., & Gozal, D. (2019) · SLEEP · doi:10.1093/sleep/zsz217 · Cited by 65
Epigenetic Regulation of Vascular Aging and Age-Related Vascular Diseases
Ding, Y.-N., Tang, X., Chen, H., & Liu, D. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1117-8_4 · Cited by 56
Wang, T., Sun, C., Hu, L., Gao, E., Li, C., Wang, H., & Sun, D. (2019) · Biochemistry and Cell Biology · doi:10.1139/bcb-2019-0057 · Cited by 54
Mitochondria in the middle: exercise preconditioning protection of striated muscle
Lawler, J. M., Rodriguez, D., & Hord, J. M. (2016) · The Journal of Physiology · doi:10.1113/jp270656 · Cited by 56
“Up-regulation of mitochondrial antioxidant enzymes, sirtuins and PGC-1 with exercise is thought to provide protection against Type II diabetes and ageing (Balestrieri et al. 2015).”
BackgroundRipa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Díaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P. R., & Kjær, A. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.012174 · Cited by 65
Sirtuin‐6 deficiency exacerbates diabetes‐induced impairment of wound healing
Thandavarayan, R. A., Garikipati, V. N. S., Joladarashi, D., Babu, S. S., Jeyabal, P., Verma, S. K., Mackie, A. R., Khan, M., Arumugam, S., Watanabe, K., et al. (2015) · Experimental Dermatology · doi:10.1111/exd.12762 · Cited by 54
Zorrilla-Zubilete, M. A., Yeste, A., Quintana, F. J., Toiber, D., Mostoslavsky, R., & Silberman, D. M. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14243 · Cited by 50
Martins, A. D., Monteiro, M. P., Silva, B. M., Barros, A., Sousa, M., Carvalho, R. A., Oliveira, P. F., & Alves, M. G. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.10.009 · Cited by 55
GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
Menghini, R., Casagrande, V., Rizza, S., & Federici, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02124-w · Cited by 59
“The relevance of the obtained results is confirmed by the evidence that compared with non-GLP-1 therapy-treated plaques, GLP-1 therapy-treated plaques presented greater SIRT6 expression and collagen content, and less inflammation and oxidative stress, indicating a more stable plaque phenotype [23].”
ResultImpact of nutrient overload on metabolic homeostasis
Qiu, H., & Schlegel, V. L. (2018) · Nutrition Reviews · doi:10.1093/nutrit/nuy023 · Cited by 56
Antioxidant and Anti-Inflammatory Activities of Buffalo Milk δ-Valerobetaine
D’Onofrio, N., Balestrieri, A., Neglia, G., Monaco, A., Tatullo, M., Casale, R., Limone, A., Balestrieri, M. L., & Campanile, G. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b07166 · Cited by 47
Self-citationSirtuin 6: A potential therapeutic target for cardiovascular diseases
Xie, S., Deng, W., & Qizhu, T. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105214 · Cited by 48
He, J., Deng, Y. J., Ren, L., Jin, Z., Yang, J., Yao, F., Liu, Y., Zheng, Z., Chen, D., Wang, B., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115952 · Cited by 53
Epigenetic Remodeling in Obesity-Related Vascular Disease
Masi, S., Ambrosini, S., Mohammed, S. A., Sciarretta, S., Lüscher, T. F., Paneni, F., & Costantino, S. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8040 · Cited by 53
“Specifically, in vitro experiments indicated that after short-term exposure to high-glucose endothelial cells and endothelial progenitor cells undergo a loss of SIRT6, which is accompanied to overexpression of NF-j B (17).”
Zhang, Z., Ren, S., Tan, Y., Li, Z.-Z., Tang, X., Wang, T., Hao, D., Zhao, X., Chen, H., & Liu, D. (2016) · Scientific Reports · doi:10.1038/srep23912 · Cited by 48
D’Onofrio, N., Pieretti, G., Ciccarelli, F., Gambardella, A., Passariello, N., Rizzo, M. R., Barbieri, M., Marfella, R., Nicoletti, G., Balestrieri, M. L., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051153 · Cited by 42
“A decreased expression of SIRT6 has been reported in the atherosclerotic plaque of diabetic patients, with a concomitant expression of higher levels of inflammatory and oxidative stress markers [15].”
BackgroundSelf-citationArsiwala, T., Pahla, J., van Tits, L. J., Bisceglie, L., Gaul, D. S., Costantino, S., Miranda, M. X., Nussbaum, K., Stivala, S., Błyszczuk, P., et al. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.01.002 · Cited by 43
Li, S., Li, S., Xiao, H., Zhang, Y., & Deng, W. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00267 · Cited by 39
SIRT6 inhibits cholesterol crystal-induced vascular endothelial dysfunction via Nrf2 activation
Jin, Z., Xiao, Y., Yao, F., Wang, B., Zheng, Z., Gao, H., Lv, X., Chen, L., He, Y., Wang, W., et al. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111744 · Cited by 39
Sirtuin Modulators in Cellular and Animal Models of Human Diseases
Hong, J. Y., & Lin, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.735044 · Cited by 43
“…and neurological disease, several sirtuins have been connected to cardiovascular diseases, like vascular aging, atherosclerosis, cardiac hypertrophy, and many more (Alcendor et al., 2004; Alcendor et al., 2007; Zhang et al., 2008; Balestrieri et al., 2015; D’Onofrio et al., 2016; Liu et al., 2016).”
BackgroundEffect of 6-gingerol on AMPK- NF-κB axis in high fat diet fed rats
Hashem, R. M., Rashed, L. A., Hassanin, K. M. A., Hetta, M. H., & Ahmed, A. O. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.035 · Cited by 48
“It is worth mentioning that the present study recoded significant increment in the lipid profile in HFD implicating the role of AMPK and Sirt-6 in affecting the metabolic status, Balestrieri and his coauthors reported that the increased Sirt-6 expression observed in diabetic plaques from the current incretin users sug…”
BackgroundDiz-Chaves, Y., Toba, L., Fandiño, J., González-Matías, L. C., Garcia-Segura, L. M., & Mallo, F. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1370-7 · Cited by 38
Nishimura, M., Morioka, T., Hayashi, M. K., Kakutani, Y., Yamazaki, Y., Kurajoh, M., Mori, K., Fukumoto, S., Shioi, A., Shoji, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0973-3 · Cited by 36
Huang, H., Wang, L., Qian, F., Chen, X., Zhu, H., Yang, M., Zhang, C., Chu, M., Wang, X., & Huang, X. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.660263 · Cited by 44
Incretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
Babenko, A. Y., Savitskaya, D. A., Kononova, Y. A., Trofimova, A. Y., Симаненкова, А. В., Vasilyeva, E. Y., & Shlyakhto, E. V. (2019) · Journal of Diabetes Research · doi:10.1155/2019/1365162 · Cited by 38
Sardu, C., Modugno, P., Castellano, G., Scisciola, L., Barbieri, M., Petrella, L., Fanelli, M., Macchia, G., Caradonna, E., Massetti, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9040401 · Cited by 36
“Indeed, the processes of atherosclerosis could be accelerated in patients with hyperglycemia [4,5].”
BackgroundInfluentialSelf-citationRole of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Ja’arah, D., Al Zoubi, M. S., Abdelhady, G., Rabi, F., & Tambuwala, M. M. (2021) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/11795514211051697 · Cited by 35
Sirtuins family as a target in endothelial cell dysfunction: implications for vascular ageing
Zhang, H., Dai, Y., Zhang, C., Alfred, M. O., Ghosh, A., Khanra, I., Chakraborty, M., Yu, X., & Liang, J. L. (2020) · Biogerontology · doi:10.1007/s10522-020-09873-z · Cited by 37
SIRT6 in Vascular Diseases, from Bench to Bedside
Ren, S., Chen, X., Gong, H., Wang, H., Wu, C. F., Li, P., Chen, X., Qu, J.-H., & Tang, X. (2022) · Aging and Disease · doi:10.14336/ad.2021.1204 · Cited by 35
Jiang, J., Zhao, L., Liu, L., Gui, M., Aleteng, Q., Wu, B., Wang, S., Pan, B., Ling, Y., & Gao, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-14152-y · Cited by 39
Dotan, I., Rudman, Y., Turjeman, ., Akirov, A., Steinmetz, T., Calvarysky, B., & Diker‐Cohen, T. (2024) · Transplantation · doi:10.1097/tp.0000000000004945 · Cited by 37
Shaikh, K. A., Kinninger, A., Cherukuri, L., Birudaraju, D., Nakanishi, R., Almeida, S. O., Jayawardena, E., Shekar, C., Flores, F. R., Hamal, S. A., et al. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8371 · Cited by 36
“Previous studies demonstrated that statin and anti-diabetic therapies may decrease the rate of coronary plaque progression and may participate in plaque stabilization (7-9).”
BackgroundLi, F.-F., Gao, G., Li, Q., Zhu, H., Su, X., Wu, J.-D., Ye, L., & Ma, J. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5347262 · Cited by 39
“Studies also demonstrated that diabetic patients with atherosclerotic plaques showed an altered and augmented inflammation and apoptosis response [34].”
BackgroundLiu, F., Bu, H., Geng, H., Plaen, I. G. D., Gao, C., Wang, P., Wang, X. Q., Kurowski, J. A., Yang, H. B., Qian, J., et al. (2017) · Molecular Medicine · doi:10.2119/molmed.2017.00085 · Cited by 31
Kamil, S., Sehested, T. S. G., Carlson, N., Houlind, K. C., Lassen, J. F., Bang, C. N., Domínguez, H., Pedersen, C. T., & Gislason, G. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1213-1 · Cited by 34
LincRNA‐p21 alleviates atherosclerosis progression through regulating the miR‐221/SIRT1/Pcsk9 axis
Wang, H., He, F., Liang, B., Jing, Y., Zhang, P., Liu, W., Zhu, B., & Dou, D. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16771 · Cited by 30
GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Chen, Y., Xu, Y.-N., Ye, C.-Y., Feng, W., Zhou, Q., Yang, D., & Wang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00836-9 · Cited by 34
“Indeed, GLP-1 mimetics were able to decrease the expression of TNF-α, MMP-9, and MMP-13 in T2DM patients [94] and suppress fibrotic phenotypes in a mouse NASH model [95].”
BackgroundSitagliptin inhibits vascular inflammation via the SIRT6-dependent signaling pathway
He, Y., Yang, G., Yao, F., Xian, Y., Wang, G., Chen, L., Lv, X., Gao, H., Zheng, Z., Sun, L., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105805 · Cited by 30
Leng, S., Li, H., Zhang, P., Dang, Z., Shao, B., Xue, S., Ning, Y., Teng, X., Zhang, L., Wang, H., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321421 · Cited by 33
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
Histone Deacetylases and Cardiometabolic Diseases
Yiew, K. H., Chatterjee, T. K., Hui, D. Y., & Weintraub, N. L. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305046 · Cited by 32
“In diabetic patients, incretin therapy was associated with SIRT6 induction, reduced inflammation and oxidative stress, and a more stable plaque phenotype.(68) Interestingly, mice treated with the HDAC inhibitor trichostatin A showed a significant and dose-dependent improvement in high-density lipoprotein cholesterol l…”
BackgroundKim, M.-J., & Yun, J. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2018.4253 · Cited by 31
Xu, J., Kitada, M., & Koya, D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165756 · Cited by 32
Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27
“…instance, in carotid endarterectomy procedures for diabetic patients, preoperative administration of GLP-1 RAs has been demonstrated to markedly enhance the expression of proteins that improve inflammatory pathways in diabetic atherosclerotic lesions, thereby promoting plaque stabilization [106].”
Wang, S., Li, L., Liang, Q., Ye, Y., Lan, Z., Dong, Q., Chen, A., Fu, M., Li, Y., Liu, X., et al. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.10.009 · Cited by 27
Elucidating emerging signaling pathways driving endothelial dysfunction in cardiovascular aging
Bartolo, A. D., Angelone, T., & Rocca, C. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107462 · Cited by 31
Metadata
- Authors
- Balestrieri, M. L., Rizzo, M. R., Barbieri, M., Paolisso, P., D’Onofrio, N., Giovane, A., Siniscalchi, M., Minicucci, F., Sardu, C., D’Andrea, D., Mauro, C., Ferraraccio, F., Servillo, L., Chirico, F., Caiazzo, P., Paolisso, G., & Marfella, R.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Ospedale Antonio Cardarelli (IT)
- Corresponding author
- Marfella, Raffaele
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-10-16
- Volume
- 64
- Issue
- 4
- Pages
- 1395-1406
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2116296155
- Cited by
- 196
- References
- 40
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 16 · 2023: 14 · 2022: 19 · 2021: 28 · 2020: 14 · 2019: 22 · 2018: 20 · 2017: 19 · 2016: 17 · 2015: 10
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- SIRT6, diabetic atherosclerosis, atherosclerotic plaque inflammation, incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, carotid plaque, plaque stability, oxidative stress, collagen content, endothelial progenitor cells, endothelial cells, high glucose, NF-κB, liraglutide, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Aged, Carotid Arteries, Collagen, Diabetes Mellitus, Type 2, Female, Humans, Inflammation, Male, Middle Aged, Endarterectomy, Carotid, Receptors, Glucagon, Oxidative Stress, Sirtuins, Incretins, Dipeptidyl-Peptidase IV Inhibitors, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.